

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Foresight Diagnostics Inc.,
Petitioner,

v.

Personalis, Inc.,
Patent Owner.

Case No. IPR2023-00317
U.S. Patent No. 11,408,033

PETITIONER'S UPDATED EXHIBIT LIST

Mail Stop: PATENT BOARD
Patent Trial and Appeal Board
U.S. Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

PETITIONER'S UPDATED EXHIBIT LIST

Ex. 1001	U.S. Patent No. 11,408,033 issued to Bartha <i>et al.</i>
Ex. 1002	Rebecca J. Leary <i>et al.</i> , “Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing,” <i>Science Translational Medicine</i> (2010) (Leary)
Ex. 1003	Stephen R. Quake <i>et al.</i> , WO 2011/057061 (Quake)
Ex. 1004	Matthew W. Anderson & Iris Schrijver, “Next Generation DNA Sequencing and the Future of Genomic Medicine,” <i>Genes</i> (2010) (Anderson)
Ex. 1005	Andreas Gnirke <i>et al.</i> , “Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing,” <i>Nature Biotechnology</i> (2009) (Gnirke)
Ex. 1006	Florian Mertes <i>et al.</i> , “Targeted enrichment of genomic DNA regions for next-generation sequencing, Briefings in Functional Genomics,” <i>Briefings in Functional Genomics</i> (2011) (Mertes)
Ex. 1007	Lira Mamanova <i>et al.</i> , “Target-enrichment strategies for next-generation sequencing,” <i>Nature</i> (2010) (Mamanova)
Ex. 1008	K.C. Allen Chan <i>et al.</i> , “Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing,” <i>Clinical Chemistry</i> (2013) (Chan)
Ex. 1009	Reserved
Ex. 1010	<i>Personalis v. Foresight</i> , First Amended Complaint, D. Colo., Case No. 1:22-v-01913, Dkt. 9, filed August, 17, 2022 (“FAC”)
Ex. 1011	Reserved
Ex. 1012	Timothy J. Ley <i>et al.</i> , “DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome,” <i>Nature</i> (2008) (Ley)
Ex. 1013	Jay Shendure and Hanlee Ji, “Next-generation DNA sequencing,” <i>Nature Biotechnology</i> (2008) (Shendure)

Ex. 1014	Jeffrey S. Ross and Maureen Cronin, “Whole Cancer Genome Sequencing by Next-Generation Methods,” <i>American Journal of Clinical Pathology</i> (2011) (Ross)
Ex. 1015	David J. McBride, et al., “Use of Cancer-Specific Genomic Rearrangements to Quantify Disease Burden in Plasma from Patients with Solid Tumors,” <i>Genes, Chromosomes & Cancer</i> (2010) (McBride)
Ex. 1016	David M. Kurtz, et al., “Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA,” <i>Nature Biotechnology</i> (2021) (Kurtz) (Ex. J to FAC)
Ex. 1017	Dennis Lo, “Cancer Genome Scanning in Plasma, Clinical Chemistry Journal,” Jan. 3, 2013 https://www.aacc.org/science-and-research/clinical-chemistry/clinical-chemistry-podcasts/2013/cancer-genome-scanning-in-plasma-detection-of-tumor-associated-copy-number-aberrations
Ex. 1018	Reserved
Ex. 1019	https://www.genome.gov/about-genomics/fact-sheets/DNA-Sequencing-Costs-Data
Ex. 1020	Declaration of John Quackenbush, Ph.D.
Ex. 1021	Declaration of Ingrid Hsieh-Yee, Ph.D.
Ex. 1022	Caroline Arbanas, “Wilson leads quest to reveal the genome's secrets,” The Source, Washington University St. Louis, April 16, 2008 https://source.wustl.edu/2008/04/wilson-leads-quest-to-reveal-the-genome-secrets/
Ex. 1023	<i>Curriculum Vitae</i> of John Quackenbush, Ph.D.
Ex. 1024	https://www.garvan.org.au/research/kinghorn-centre-for-clinical-genomics/learn-about-genomics/for-gp/genetics-refresher-1/types-of-variants

Ex. 1025	Reserved
Ex. 1026	Leary Supplemental Information
Ex. 1027	Hugo Lam, et al., “Performance comparison of whole-genome sequencing platforms,” <i>Nature Biotechnology</i> (2012) (Lam)
Ex. 1028	Illumina, Technical Note: Sequencing
Ex. 1029	Illumina, Specification Sheet: Illumina Sequencing
Ex. 1030	Tim Forshew, et al., “Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA,” <i>Science Translational Medicine</i> (2012) (Forshew)
Ex. 1031	Matthew Meyerson, et. al., “Advances in understanding cancer genomes through second-generation sequencing,” <i>Nature Reviews</i> (2010) (Meyerson)
Ex. 1032	Forshew Supplemental Information
Ex. 1033	Nikhil Wagle et al., “High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing,” <i>Cancer Discovery</i> (2012) (Wagle)
Ex. 1034	Andreas Untergasser <i>et al.</i> , “Primer3—new capabilities and interfaces,” <i>Nucleic Acids Res.</i> (2012) (Untergasser)
Ex. 1035	Simon Forbes <i>et al.</i> , “COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer,” <i>Nucleic Acids Res.</i> (2011) (Forbes)
Ex. 1036	Y. Kohara, “DNA probes on beads arrayed in a capillary, 'Bead-array', exhibited high hybridization performance,” <i>Nucleic Acids Res.</i> (2002) (Kohara)
Ex. 1037	Infringement Claim Chart for U.S. Patent No. 11,408,033; Ex. O to Patent Owner’s FAC

Ex. 1038	C. Vale <i>et al.</i> , “Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.” Cancer Treat Rev. (2012) (<i>Vale</i>)
Ex. 1039	Wagle Supplementary Tables
Ex. 1040	Reserved
Ex. 1041	Reserved
Ex. 1042	Reserved
Ex. 1043	Reserved
Ex. 1044	Reserved
Ex. 1045	Reserved
Ex. 1046	Reserved
Ex. 1047	Reserved
Ex. 1048	Reserved
Ex. 1049	Reserved
Ex. 1050	Reserved
Ex. 1051	Reserved
Ex. 1052	Reserved
Ex. 1053	Reserved
Ex. 1054	Reserved
Ex. 1055	Reserved
Ex. 1056	Reserved
Ex. 1057	Reserved
Ex. 1058	Reserved
Ex. 1059	Reserved

Ex. 1060	Reserved
Ex. 1061	Reserved
Ex. 1062	Reserved
Ex. 1063	Reserved
Ex. 1064	Reserved
Ex. 1065	Reserved
Ex. 1066	Reserved
Ex. 1067	Reserved
Ex. 1068	Reserved
Ex. 1069	Reserved
Ex. 1070	Reserved
Ex. 1071	Reserved
Ex. 1072	Reserved
Ex. 1073	Reserved
Ex. 1074	Reserved
Ex. 1075	Reserved
Ex. 1076	Reserved
Ex. 1077	Reserved
Ex. 1078	Additional Excerpts from Application No. 14/810,337 (EX2004)

IPR2023-00317
U.S. Patent No. 11,408,033

Dated: April 14, 2023

Respectfully submitted,

/Andrew E. Krause/

Andrew E. Krause, Reg. No. 76,276
IRELL & MANELLA LLP
1800 Avenue of the Stars, Ste. 900
Los Angeles, CA 90067
(310) 203-7668
akrause@irell.com

Amir Naini, Reg. No.
NAINI P.C.
2632 Wilshire Blvd., Suite 268
Santa Monica, CA 90403
(310) 592-3030
amir@nainipc.com

Attorneys for Petitioner
Foresight Diagnostics Inc.

CERTIFICATE OF SERVICE

I hereby certify, pursuant to 37 C.F.R. section 42.6, that on April 14, 2023, a complete copy of the foregoing document **PETITIONER'S UPDATED EXHIBIT LIST** was served upon the following, by ELECTRONIC MAIL:

WEIL, GOTSHAL & MANGES LLP

Derek C. Walter, Lead Counsel
Derek.walter@weil.com

Adrian Percer, Backup Counsel
Adrian.percer@weil.com

Personalis.Foresight@weil.com

/Susan M. Langworthy/
Susan M. Langworthy